Literature DB >> 2295405

Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum.

B L Ungar1, D J Ward, R Fayer, C A Quinn.   

Abstract

Cryptosporidium is a parasite of the human gastrointestinal tract that can cause life-threatening diarrhea in immunodeficient patients. Although more than 80 agents have been tried with occasional anecdotal success, treatment remains primarily limited to hydration. A 38-yr-old homosexual man with antibody to human immunodeficiency virus and Cryptosporidium-related diarrhea is described. The patient excreted 6-12 L of stool per day for at least 3 mo, 2 of them spent in the hospital. Trials with more than 6 antidiarrheal medications were ineffective. The patient received bovine colostrum hyperimmune to Cryptosporidium by direct duodenal infusion. During infusion, the patient's fecal output decreased to less than 2 L per day, and 48 h after treatment, stools were formed and oocysts to Cryptosporidium were absent. The patient remained asymptomatic for 3 mo. Hyperimmune bovine colostrum offers an exciting new therapy for cryptosporidiosis; controlled trials to establish efficacy should be undertaken and the active factor(s) characterized.

Entities:  

Mesh:

Year:  1990        PMID: 2295405     DOI: 10.1016/0016-5085(90)90842-o

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  Chronic diarrhea: causes, presentation, and management.

Authors:  D I Mehta; E Lebenthal; U Blecker
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

3.  Effect of bovine colostrum-based food supplement in the treatment of HIV-associated diarrhea in Northern Uganda: a randomized controlled trial.

Authors:  F O Kaducu; S A Okia; G Upenytho; L Elfstrand; C-H Florén
Journal:  Indian J Gastroenterol       Date:  2011-12-13

Review 4.  Therapeutic potentials of bovine colostrums.

Authors:  B R Thapa
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

Review 5.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

6.  Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum.

Authors:  J M Bjorneby; B D Hunsaker; M W Riggs; L E Perryman
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Enteral human serum immunoglobulin treatment of cryptosporidiosis in mice with severe combined immunodeficiency.

Authors:  T L Kuhls; S L Orlicek; D A Mosier; D L Crawford; V L Abrams; R A Greenfield
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection.

Authors:  F J Enriquez; M W Riggs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Cloning and expression of a cDNA encoding epitopes shared by 15- and 60-kilodalton proteins of Cryptosporidium parvum sporozoites.

Authors:  M C Jenkins; R Fayer; M Tilley; S J Upton
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

10.  Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo.

Authors:  P S Doyle; J Crabb; C Petersen
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.